Propafenone efficacy in treatment of atrial fibrillation paroxysms: a placebo-controlled study
In a placebo-controlled study, propafenone efficacy and safety for pharmaceutical cardioversion in atrial fibrillation (AF) paroxysms were studied. The study included 50 patients aged 28-69 years (mean age 53,9+9,7), with AF paroxysms lasting for less than 48 hours. Participants were randomized to p...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
«FIRMA «SILICEA» LLC
2005-12-01
|
| Series: | Российский кардиологический журнал |
| Subjects: | |
| Online Access: | https://russjcardiol.elpub.ru/jour/article/view/2343 |
| id |
doaj-e9a135cf00344fe6a7c80ecb8a27bf69 |
|---|---|
| record_format |
Article |
| spelling |
doaj-e9a135cf00344fe6a7c80ecb8a27bf692021-07-28T14:02:07Zrus«FIRMA «SILICEA» LLC Российский кардиологический журнал1560-40712618-76202005-12-010657612089Propafenone efficacy in treatment of atrial fibrillation paroxysms: a placebo-controlled studyYu. A. Bunin0L. K. Anfalova1Российская медицинская академия последипломного образованияРоссийская медицинская академия последипломного образованияIn a placebo-controlled study, propafenone efficacy and safety for pharmaceutical cardioversion in atrial fibrillation (AF) paroxysms were studied. The study included 50 patients aged 28-69 years (mean age 53,9+9,7), with AF paroxysms lasting for less than 48 hours. Participants were randomized to propafenone (single dose of 600 mg, per os) or placebo. Eight hours later, sinus rhythm was restored in propafenone group more effectively than in placebo group: 85,7% and 33,3%, respectively (p=0,001). Mean sinus rhythm restoring time was 2,5+1,9 and 3,8+1,5 hours, respectively.https://russjcardiol.elpub.ru/jour/article/view/2343atrial fibrillationcardioversionpropafenone |
| collection |
DOAJ |
| language |
Russian |
| format |
Article |
| sources |
DOAJ |
| author |
Yu. A. Bunin L. K. Anfalova |
| spellingShingle |
Yu. A. Bunin L. K. Anfalova Propafenone efficacy in treatment of atrial fibrillation paroxysms: a placebo-controlled study Российский кардиологический журнал atrial fibrillation cardioversion propafenone |
| author_facet |
Yu. A. Bunin L. K. Anfalova |
| author_sort |
Yu. A. Bunin |
| title |
Propafenone efficacy in treatment of atrial fibrillation paroxysms: a placebo-controlled study |
| title_short |
Propafenone efficacy in treatment of atrial fibrillation paroxysms: a placebo-controlled study |
| title_full |
Propafenone efficacy in treatment of atrial fibrillation paroxysms: a placebo-controlled study |
| title_fullStr |
Propafenone efficacy in treatment of atrial fibrillation paroxysms: a placebo-controlled study |
| title_full_unstemmed |
Propafenone efficacy in treatment of atrial fibrillation paroxysms: a placebo-controlled study |
| title_sort |
propafenone efficacy in treatment of atrial fibrillation paroxysms: a placebo-controlled study |
| publisher |
«FIRMA «SILICEA» LLC |
| series |
Российский кардиологический журнал |
| issn |
1560-4071 2618-7620 |
| publishDate |
2005-12-01 |
| description |
In a placebo-controlled study, propafenone efficacy and safety for pharmaceutical cardioversion in atrial fibrillation (AF) paroxysms were studied. The study included 50 patients aged 28-69 years (mean age 53,9+9,7), with AF paroxysms lasting for less than 48 hours. Participants were randomized to propafenone (single dose of 600 mg, per os) or placebo. Eight hours later, sinus rhythm was restored in propafenone group more effectively than in placebo group: 85,7% and 33,3%, respectively (p=0,001). Mean sinus rhythm restoring time was 2,5+1,9 and 3,8+1,5 hours, respectively. |
| topic |
atrial fibrillation cardioversion propafenone |
| url |
https://russjcardiol.elpub.ru/jour/article/view/2343 |
| work_keys_str_mv |
AT yuabunin propafenoneefficacyintreatmentofatrialfibrillationparoxysmsaplacebocontrolledstudy AT lkanfalova propafenoneefficacyintreatmentofatrialfibrillationparoxysmsaplacebocontrolledstudy |
| _version_ |
1721269744870359040 |